Paul, Weiss and Kirkland & Ellis advised on AbbVie’s acquisition of Apogee Therapeutics in an all-cash transaction valued at approximately US$10.9 billion.
Under the terms of the agreement, AbbVie will acquire all outstanding shares of Apogee for US$135.11 per share in cash. The acquisition complements AbbVie’s existing immunology portfolio and expands its clinical presence in the respiratory disease space. The boards of directors of both companies unanimously approved the transaction, which is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals and other customary closing conditions.
Paul, Weiss advised AbbVie on the transaction.
The Paul, Weiss team is led by corporate partners Krishna Veeraraghavan and Benjamin Goodchild, and includes corporate partners Julie Ann Lamm and Patricia Vaz de Almeida; intellectual property partners Jeffrey Osterman and Brianna van Kan; executive compensation partner Matthew Friestedt; tax partner Brian Krause; antitrust partners Scott Sher, Jesse Solomon, Nicole Kar and Lauren O’Brien; litigation partners Elizabeth Weiswasser, Mark Mendelsohn and Geoffrey Chepiga, and counsel Audrey Paquet, Natalie Kennedy, Benjamin Klein and Josh Thompson; and real estate partner Ida Nowaid.
Kirkland & Ellis advised Apogee Therapeutics on the transaction.
The Kirkland team included corporate lawyers Graham Robinson and Chadé Severin; technology & IP transactions lawyers Shellie Freedman and Rami Sherman; antitrust & competition lawyer Maria Raptis; and executive compensation lawyer Tim Nelson.
The deal reporting on this platform is based on the information received from law firms, and therefore, some details may be missing/incomplete. If your firm has not been credited for this deal, write to us at chanchal.makhija@thegreymatter.co.in mentioning your firm’s name, lawyers involved (including designation) and client represented.
